by The global Postpartum Depression Drug Market is estimated to be valued at Us$ 6.65 Bn in 2023 and is expected to exhibit a CAGR Of 30% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Postpartum depression, also called postnatal depression, is a type of mood disorder experienced by women within four weeks after childbirth. It is estimated that 1 in 9 women experience postpartum depression. The condition is caused due to hormonal and physical changes and the demands of a new baby. Symptoms include sadness, anxiety, tearfulness, irritability, loss of interest in the baby and feelings of inadequacy as a parent. Postpartum depression is usually treated with antidepressants from the selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) classes. Some commonly prescribed postpartum depression drugs include sertraline, fluoxetine, paroxetine and duloxetine. These drugs act by increasing levels of serotonin and other neurotransmitters in the brain to alleviate symptoms. With the growing awareness about postpartum depression and availability of treatment drugs, the market is expected to witness significant growth over the forecast period.
Market Key Trends:
One of the key trends driving growth in the postpartum depression drug market is the increasing approval and launch of new drug formulations. For instance, in 2019, the US FDA approved the first non-hormonal drug brexanolone (Zulresso) for treatment of postpartum depression. It works faster than traditional antidepressants. Similarly, in 2021, the FDA granted accelerated approval to SAGE-217 for treatment of major depressive disorder in adults. Such drug pipeline expansion and new product approvals are fueling growth of the market. Furthermore, rising vaccination rates against Covid-19 pandemic are allowing more in-person doctor visits and screenings for postpartum depression, thereby aiding early diagnosis and treatment with drugs.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is low in the postpartum depression drug market due to the high costs associated with R&D and clinical trials for new drug approvals. The market also has the presence of major pharmaceutical companies with strong brand recognition and distribution networks.
Bargaining power of buyers: The bargaining power of buyers is high due to the presence of generic drug manufacturers providing alternatives at lower prices. Buyers have the option to switch to alternative therapies available.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as the raw material suppliers have minimal differentiation in their products. However, the industry depends on only a few suppliers for active pharmaceutical ingredients.
Threat of new substitutes: The threat of substitutes is moderate as alternative therapies like psychotherapy, yoga, and herbal supplements provide effective treatment. New drug delivery methods can also emerge as substitutes.
Competitive rivalry: High due to the number of patented drugs and strong pipeline of candidates.
Key Takeaways
The Global Postpartum Depression Drug Market Demand is expected to witness high growth, exhibiting CAGR of 30% over the forecast period, due to increasing awareness about mental health issues and the availability of several drug formulations.
Regionally, North America dominated the market with over 40% share in 2023 due to rising healthcare expenditure and presence of major pharmaceutical companies in the US. However, Asia Pacific is projected to witness fastest growth owing to growing middle-class population and healthcare infrastructure development in China and India.
Key players operating in the postpartum depression drug market are Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Bayer AG (Germany), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (US), Cipla Inc. (US), Aurobindo Pharma (India), Lupin (India), Accord Healthcare (US), Sun Pharmaceutical Industries Ltd. (India), Bausch Health Companies Inc. (Canada), Alvogen (US), Intas Pharmaceuticals Ltd. (India), SHIONOGI & Co., Ltd. (Japan). Key players are focused on new product launches and accelerating clinical trials to expand their market share.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
